Delcath Systems Reports Second Quarter 2026 Results and Business Highlights
Delcath Systems reported Q2 2026 revenue of $29.1 million, up from $24.2 million in the prior year, driven by a 30% increase in HEPZATO volume and expanding gross margins to 90%. The company generated $5.7 million in cash from operations and maintained a net income of $2.7 million. Management raised full-year 2026 revenue guidance to a range of $104 million to $108 million, reflecting confidence in the adoption of HEPZATO across 31 active treatment centers.
Key figures
- Eps
- 0.07
- Revenue
- 29100000
- Guidance
- Total HEPZATO KIT and CHEMOSAT revenue to range from $104 million to $108 million
- Rd expenses
- 10400000
- Gross margin
- 90%
- Adjusted ebitda
- 7600000
- Cash and investments
- 95900000
- Cash flow operations
- 5700000
- Hepzato volume growth
- 30%
AI analysis
Red flags1 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.